Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Bad financial results growth rate -3.4% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-7.2%)
  • Dividend yield for the last twelve months 3.6%
  • Free cash flow yield -1.7% (LTM)
  • Share price is 33.0% higher than minimum and 13.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (28.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $0.3 mln (0.000% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+2.4%)175.58
year average price 176.82  


year start price 154.94 2023-12-23

min close price 154.62 2023-12-26

max close price 203.87 2024-10-31

current price 175.58 2024-12-21
Common stocks: 1 768 480 508

Dividend Yield:  3.6%
FCF Yield LTM: -1.7%
EV / LTM EBITDA: 28.3x
EV / EBITDA annualized: 22x
Last revenue growth (y/y):  +4.3%
Last growth of EBITDA (y/y):  -11.1%
Historical revenue growth:  +0.9%
Historical growth of EBITDA:  -15.4%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 310 510
Net Debt ($m): 57 520
EV (Enterprise Value): 368 030
EBITDA LTM ($m): 13 022
EV / LTM EBITDA: 28.3x
Price to Book: 51.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-12-19fool.com

2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond

2024-12-18zacks.com

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

2024-12-17zacks.com

4 Big Drug Stocks That May Continue to Outperform in 2025

2024-12-16zacks.com

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors

2024-12-16seeitmarket.com

Why Investors Should Watch AbbVie Inc (ABBV)

2024-12-16seekingalpha.com

AbbVie: Pullback Is A Golden Opportunity For Dividend And Growth Investors

2024-12-16forbes.com

AbbVie Enters Oversold Territory

2024-12-16zacks.com

ABBV's Acquisition Spree Continues: Buy, Sell or Hold the Stock?

2024-12-16zacks.com

ABBV to Acquire Nimble Therapeutics to Strengthen Immunology Pipeline

2024-12-15fool.com

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data